SCHEMBL19924929

SCHEMBL19924929

Brc1nccn1Cc1ccncc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.39
LMNA P02545 1/20 0.39
KDM4E B2RXH2 1/20 0.38
HSP90AA1 P07900 1/20 0.38
USP2 O75604 1/20 0.38
MAPK10 P53779 1/20 0.38
NPSR1 Q6W5P4 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CYP19A1 P11511 1/20 0.37
CYP11B2 P19099 1/20 0.37
HDAC8 Q9BY41 2/20 0.37
HDAC6 Q9UBN7 2/20 0.37
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19925275 0.85 HSD17B10 (0.51) CYP11B1L3MBTL1KDM4EHSP90AA1HSD17B10
SCHEMBL19925311 0.79 CYP11B1 (0.50) CYP11B1L3MBTL1KDM4EHSP90AA1HDAC8
SCHEMBL28418471 0.72 RAB9A (0.49) KDM4EALDH1A1FLT1KDR
SCHEMBL19924908 0.70 ALDH1A1 (0.45) LMNAKDM4EHSD17B10HDAC8HDAC6
SCHEMBL24937329 0.69 HTR6 (0.40) CYP11B1L3MBTL1LMNAKDM4EUSP2
SCHEMBL2887633 0.69 SCN9A (0.42) CYP11B1L3MBTL1KDM4EUSP2MAPK10
SCHEMBL5533142 0.69 CYP11B1 (0.49) CYP11B1L3MBTL1LMNAHSP90AA1HSD17B10
SCHEMBL4509139 0.69
SCHEMBL2840217 0.68 LIMK2 (0.58) KDM4EHSD17B10ALDH1A1
SCHEMBL26129994 0.68 CYP11B1 (0.47) CYP11B1L3MBTL1LMNAHSP90AA1CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3507281-A1 IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2019-07-10 EP disclosed
US-20190202799-A1 IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2019-07-04 US disclosed
US-20190202799-A1 IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2019-07-04 US disclosed
WO-2018041964-A1 IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-03-08 WO disclosed
WO-2018041964-A1 IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190202799-A1 IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS BRD4, BRPF3, BRD3 CYP11B1 2425/4885L3MBTL1 2184/4885LMNA 3849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.